Ketamine has shown effectiveness as a rapidacting antidepressant with antisuicidal effects in terms of reduction of suicidal ideation in the short term. However, the evidence for long-term maintenance ketamine therapy for treatmentresistant depression (TRD) and suicidal behavior is limited. This case series (N = 13) highlights the role of adjunctive serial maintenance ketamine infusions in restoring functionality in treatmentresistant unipolar and bipolar (mixed) depression with significant suicide risk and multiple comorbidities, including alcohol dependence. Two cases of TRD achieved functional remission with long-term maintenance ketamine treatment. The first case illustrates the potential synergistic interaction between ketamine and
Introduction
The widespread and intense interest surrounding ketamine as a "novel" antidepressant 1 has been tempered by calls for caution with regard to the premature heralding of ketamine as the "clozapine for depression." 2 The purported robust effectiveness of ketamine, as evidenced by the 2015 meta-analysis of Newport et al, 3 was confined to transient antidepressant effects (24 h to 2 wk) of single-dose regimens in 7 double-blind, randomized, placebo-controlled trials (RCTs). The evidence for longer term effectiveness is comparatively limited. However, data are gradually emerging that are suggestive of higher acute response rates and lower posttreatment relapse rates with serial compared with single-dose ketamine infusions. In an open-label series involving 24 patients with treatment-resistant unipolar depression, Murrough et al 4 found that thrice-weekly serial 0.5 mg/kg ketamine, administered over 40 minutes as monotherapy treatment for 12 days, yielded a 70.8% response rate, with a median time to relapse of 18 days. Rasmussen et al 5 reported that twice weekly serial ketamine infusions, administered at a slower rate of 100 minutes for up to 2 weeks as adjunctive therapy, in an open-label series of 10 patients with treatment refractory unipolar or bipolar depression produced an 80% overall response rate and a 50% remission rate in the acute phase, with 40% of those patients remaining in remission after 4 weeks. Reported psychotomimetic side effects and increases in blood pressure in these studies were mainly transient without serious sequelae. Other studies have not found significant cognitive side effects after serial ketamine infusions after 4 weeks 6 or 6 months 7 of naturalistic follow-up.
In addition to ketamine's antidepressant effect, its potential as an antisuicidal agent has also generated considerable excitement, as, aside from lithium and clozapine's antisuicidal properties, psychiatry is still lacking a rapidly acting pharmacological intervention for suicide. Two meta-analyses 3, 8 and a review, 9 have identified 17 published reports that showed a significant reduction of suicidal ideation with ketamine therapy in patients with suicidal ideation, including 1 study in the emergency department. Eleven reports included patients with major depressive disorder and 6 with bipolar disorder. Twelve of the reports involved patients with unipolar or bipolar treatment-resistant depression (TRD). There were 6 RCTs, 8 open-label studies, and 3 case reports. The majority of these studies involved a single ketamine dose, whereas 4 studies used serial ketamine infusions. 5, 7, 10, 11 It is debatable whether ketamine's antisuicidal effect is distinct from its general antidepressant and antianxiety effects. 2 Nevertheless, there is accumulating evidence in support of ketamine's suicide-specific properties being somewhat independent from its antidepressant and antianxiety effects. 10, 12, 13 A number of predictors of a favorable antidepressant response to ketamine have been found in single-dose studies (ie, higher body mass index, family history of alcohol use disorder, 14 no history of suicide attempts, 15 presence of dissociative side effects, 16 lower pretreatment cognitive measures of attention and processing speed, 17 and male sex 18 ). Interestingly, a history of a suicide attempt predicted antisuicidal response in a serial infusion study, 12 whereas a single-dose study found that lack of a previous suicide attempt predicted a good antidepressant response, as noted above. 15 Other predictors of antisuicidal response that have been reported include previous psychiatric hospitalization, a family history of alcohol abuse (similar to antidepressant response), history of sexual abuse, and a trend of suicide attempts in the family history, as seen in a 2017 single-dose ketamine study by Yarrington et al. 19 Potential biomarkers of an antidepressant response to ketamine include the brain-derived neurotrophic factor, Val66Met polymorphism, 20 plasma brain-derived neurotrophic factor levels after ketamine treatment, 21 levels of D-serine before ketamine treatment, 22 and interleukin-6 and interleukin-1β. 23 To date, significant gaps exist in our understanding of the effectiveness of maintenance ketamine as an antidepressant and antisuicidal agent, particularly in the longer term. Studies that have included naturalistic follow-up ranging from 3 months 10 to 12 months 24 have been limited by their open-label and uncontrolled designs.
In this report, we highlight the management challenges in 2 cases of TRD treated with maintenance intravenous ketamine infusions, focusing on the factors associated with antidepressant and antisuicidal response, as well as on long-term safety and tolerability aspects. Our first case was a patient diagnosed with treatment-resistant bipolar II depression, with mixed hypomanic features and multiple psychiatric comorbidities, who was given maintenance ketamine infusions for a total of 7 months. The second case was a patient with unipolar TRD, who, to the best of our knowledge, is the patient who has been treated for the longest duration with maintenance ketamine infusions to be reported in the published literature, having been treated with ketatmine for a total of 5 years.
Case Report 1
In January 2017, patient 1, a Malaysian Chinese artist in her late 20s, was hospitalized in the psychiatric ward for a relapse of treatment-resistant bipolar II depression with mixed hypomanic features. Her comorbid diagnoses included social anxiety disorder, cluster B personality traits, and alcohol use disorder. She had a first-degree relative with alcohol dependence.
Two weeks before her hospitalization, the patient reported feeling increasingly depressed [total score of 23 on the 16-item Self-Report Quick Inventory of Depressive Symptomatology (QIDS-SR16)], 25 with concurrent hypomanic symptoms associated with suicidal obsessions 26 and agitation. She reported having vivid images of herself slashing her wrist and hanging herself, and eventually attempted to jump off the eighth floor of a building, but was rescued in time. At that time, the patient was experiencing relationship problems.
Before her hospitalization, the patient was on a combination of lithium (300 mg twice daily, blood levels of 0.24 to 0.53 mmol/L), clonazepam (2 mg twice daily) alprazolam (0.5 mg 3 times daily), and asenapine (2.5 mg at night). However, she was unable to tolerate the sedative effect of the asenapine and was switched to aripiprazole (2.5 mg/d) just before her hospitalization. In addition, at the time of her hospitalization, the patient had received 11 sessions of daily left prefrontal low-frequency repetitive transcranial magnetic stimulation (rTMS) between December 22, 2016, and January 10, 2017. Previous treatments to which the patient had had an inadequate response included escitalopram (10 mg at night), fluvoxamine (100 mg at night), duloxetine (120 mg/d), olanzapine (5 mg at night), aripiprazole (5 mg/d), quetiapine (stopped because of the patient's concerns about weight gain), and vortioxetine, as well as a course of electroconvulsive therapy (ECT) (6 bilateral sessions) before 2016.
Patient 1 had also received a second course of ECT as an inpatient during a previous relapse 4 months before this current episode in January 2017. She had presented with similar symptoms and a suicide attempt in which she cut her wrist after breaking up with her boyfriend. At that time, she showed a partial response to 12 sessions of thrice-weekly bilateral ECT and 1 unilateral ECT between September and October 2016. Her suicidal ideation resolved, and her QIDS-SR16 total score dropped from 24 (pre-ECT) to 16 (post-ECT). Unfortunately, the ECT had to be discontinued because of significant retrograde and anterograde amnesia, with a Montreal Cognitive Assessment score of 25/30. These cognitive side effects significantly affected the patient's functioning, as she was unable to learn new steps for her dance performances, which contributed to worsening depressive symptoms and increased alcohol use.
In view of the patient's prominent suicidality and severe treatment-resistant bipolar depression, which included failed ECT trials, the option of ketamine infusion treatment was discussed with the patient. Ketamine infusion treatment for treatment-resistant mood disorders has been established as a clinical service at our center since 2009. The discussion with the patient and her immediate family included potential benefits (rapid antidepressant and antisuicidal effects) and side effects (risk of manic switch, transient hemodynamic instability, dissociative symptoms, and perceptual disturbances) of ketamine infusion treatment. 17 The off-label use of ketamine as a treatment for treatment-resistant mood disorders was also highlighted. The patient then gave informed consent for the ketamine infusion treatment.
The first dose (0.5 mg/kg) of ketamine infusion was administered on January 11, 2017, over 90 minutes. 5 During the ketamine infusion, the patient was observed to be more talkative. She described herself as feeling more friendly and chatty with a mixture of emotions. At one point during the infusion, the patient felt transiently depressed and had the urge to cut herself; however, this resolved, and she later described her mood as normal, without any elation for about an hour, immediately after the ketamine infusion. She experienced transient derealization once during the ketamine infusion, which resolved after the infusion was completed. She also reported having a sore throat for 2 to 3 days after each ketamine infusion. This resolved after the omission of the intravenous glycopyrrolate (100 mcg), which was administered each time before the ketamine infusion to reduce secretions. Interestingly, even though her total QIDS-SR16 score only showed a minimal reduction from 23 before ketamine treatment to 20 after ketamine treatment, the QIDS-SR16 item-12 on suicidality dropped from a maximum score of 3 ("I think of suicide or death several times a day in some detail, or I have made specific plans for suicide or have actually tried to take my life") to a score of 1 ("I feel that life is empty or wonder if it's worth living"). The patient described the antidepressant and antisuicidal effect of ketamine as short-lived, as her mood would return to being depressed within an hour after the ketamine infusion. Hence, a 3 times weekly dosing schedule was initially planned for this patient.
With regard to the patient's other medications, lithium (300 mg in the morning, 600 mg at night) was stopped between the first and second dose of ketamine because of the development of asymptomatic sinus bradycardia (heart rate 36 to 39 bpm) at neartoxic levels of 1.2 mMol/L. There were no other clinical signs and symptoms of lithium toxicity. The third dose of ketamine was stopped after 15 minutes of infusion, because of bradycardia (heart rate 46 bpm), which was again asymptomatic. The patient's heart rate gradually normalized to 60 to 90 bpm 10 days after lithium was discontinued. Subsequent ketamine infusions (doses 4 to 16) were administered twice a week over the next 6 weeks to mitigate the risk of the patient developing ketamine tolerance, 27 as the patient had reported a subjective waning of the antidepressant effect of ketamine after the third thrice-weekly (3 times/wk) dose, with the antidepressant effect lasting <1 hour after the ketamine infusion. After the seventh ketamine infusion, the patient started to notice a more substantial change in her mood, which was reflected by some improvement in functioning. For example, she requested home leave and was able to do some parttime artistic work over the weekend, in spite of the presence of mood fluctuations and a somewhat static QIDS-SR16 total score of 19 to 20. The patient was then able to articulate the significance of social anxiety as a triggering factor for her depression and suicidal thoughts when she was faced with having to interact with strangers while at work. She was then referred to a doctoral-level psychologist for cognitive behavioral therapy (CBT) for her social anxiety disorder; she had 5 intensive sessions of inpatient, graded exposure, followed by a few booster sessions. After her tenth ketamine infusion, the patient had a mild relapse of depression (QIDS-SR16 total score of 21) and a resurgence of suicidal thoughts (QIDS-SR16 item-12 score of 3), which was related to her relationship issues. She was started on lamotrigine at 12.5 mg/d and the dose of aripiprazole was maximized to 20 mg/d, in addition to being switched from twice a week to weekly ketamine infusions of 0.5 mg/kg at her 17th ketamine infusion. Her mood gradually improved, and she was well enough to be discharged, after the 18th dose of ketamine and 2 months of inpatient care. During the period between her 11th and 22nd ketamine sessions, the patient was also taught mindfulness techniques. 28, 29 The patient reported that the mindfulness techniques, which she found more helpful than deep breathing and progressive muscle relaxation, subjectively reduced her levels of anxiety, but not her depression or suicidal thoughts.
The patient continued to be fairly well and was able to sustain a part-time job for about 3 months before she had another relapse-a depressive episode with mixed features-associated with prominent guilt with suicidal ideation, with a QIDS-SR16 total score of 23 and an item-12 score of 2. Possible stressors that may have contributed to this relapse included interpersonal relationship issues and an episode of cannabis use and an alcohol binge. The patient's mood improved gradually, after the dose of lamotrigine was optimized to 200 mg/d and the successful tapering of benzodiazepines, when the patient's social anxiety symptoms were better controlled with CBT. Alprazolam was discontinued and clonazepam was reduced to 0.5 mg twice per week on average. She received 3 infusions in week 1 and 13 infusions in weeks 2 through 8 (administered twice weekly). After a total of 42 doses of ketamine infusions (administered at weekly intervals starting 2 mo after her first ketamine infusion) over 7 months, in combination with 2 mood stabilizers (lamotrigine 200 mg/d and aripiprazole 20 mg/d), her depressive symptoms remitted, and the suicidal ideation resolved completely. The QIDS-SR16 total score dropped from 23 (before the first dose of ketamine) to 4 (after dose 42 of ketamine), and the score on QIDS-SR16 item-12 dropped to 0. In addition, her cognitive tests also improved, and she scored 30/30 on the Montreal Cognitive Assessment. The patient is currently able to sustain part-time artistic work. Between ketamine doses 42 and 43, she experienced residual social anxiety symptoms when she decided to start a part-time Bachelor's degree program and stopped attending group dance classes. Although there were mild fluctuations in her depressive symptoms at that time (QIDS-SR16 total score of 10 after dose 43 of ketamine), she was no longer suicidal. She has also remained relatively sober from alcohol since the initiation of ketamine treatment (with the exception of 2 alcohol binges during relapse episodes) and is currently in a relatively stable relationship. Because of the potential risk of ketamine-induced cystitis, 30 monthly urinalyses were performed with results normal throughout the course of the maintenance ketamine infusion treatment, and the patient did not report any urinary symptoms. The course of the patient's response to treatment is shown in Figure 1 .
Case Report 2
Patient 2 is a Malaysian Chinese retired educator in her late 50s who experienced her first episode of major depressive disorder 27 years ago. Her current diagnosis is treatment-resistant persistent depressive disorder with persistent major depressive episode. She does not have any history of substance abuse, but she does have a family history of alcohol dependence in a first-degree relative. She has had previous unsuccessful trials of antidepressants including paroxetine, fluoxetine, mirtazapine, lithium, venlafaxine, mianserin, and sertraline. Psychosocial interventions she has received include CBT and multiple family sessions focusing on psychoeducation and reducing high expressed emotion to address family dynamics, for example, the patient's anxieties and expectations with regard to her children's academic and professional future as well as her role as the family's main breadwinner.
In The patient had received a total of 131 ECT administrations (79 bilateral and 52 unilateral) between 2001 and 2012. Nevertheless, the ECT treatment was insufficiently effective, producing an inadequate response, which was complicated by significant cognitive deficits after ECT. The patient's occupational functioning was so severely impaired that an issue arose with regard to the risk of her being medically "boarded out" of work (ie, termination of employment on the grounds of incapacity to work because of a psychiatric disorder). The patient expressed her wish to be well enough to continue working to support her children's education. In August 2012, she gave informed consent for maintenance ketamine infusion therapy after a comprehensive discussion about the potential benefits and side effects of the off-label use of ketamine in TRD. Ketamine infusion therapy was initiated at 0.5 mg/ kg over 60 minutes at a dosing schedule of once every 3 to 5 weeks. The patient reported a favorable response to ketamine, with significant improvement in her energy level and significant reduction in anhedonia and insomnia, and a subjective 70% improvement of depression overall. The patient's total scores on the Beck Depression Inventory (BDI) 31 were 27 before her first ketamine dose and 20 after that first dose. The patient's functionality improved markedly, so that she was able to concentrate and sustain consistent work as an educator for 3 years after the initiation of ketamine infusions in 2012 until her retirement in 2015, when she had completed financing her children's education (lowest BDI total score of 7 in April 2015).
The patient experienced a mild relapse of depression, in July 2017, precipitated by her son's hospitalization owing to dengue fever. At that time, she also reported experiencing worsening insomnia that had started to occur after being switched from quetiapine XR to the immediate release formulation of quetiapine because of a change in medication funding policy. In addition, she reported symptoms of hopelessness, passive suicidal ideation, severe insomnia, and her BDI scores were 20 (before ketamine treatment) and 13 (after ketamine treatment), respectively. The patient's depressive symptoms improved, and suicidal ideation resolved after her son recovered from dengue fever. She also felt much relieved when her insomnia improved after switching to quetiapine XR (800 mg/d). Her BDI scores in September 2017 were 15 (before FIGURE 1. Response to ketamine infusions in case report 1.
Note: Line discontinuity for after ketamine infusion QIDS-SR16 total score due to some missing data. ECT indicates electroconvulsive therapy; QIDS-SR16, 16-item Self-Report Quick Inventory of Depressive Symptomatology; rTMS, repetitive transcranial magnetic stimulation. Initial adverse effects that the patient experienced with ketamine infusions included sedation and depersonalization (during infusion), giddiness (2 to 3 d after infusion), and nausea (1 wk after infusion), but these were transient and were not debilitating in terms of functioning. These side effects resolved after the infusion rate was slowed down to 90 instead of the initial 60 minutes. The patient did not report any urinary symptoms, and her urinalysis results were normal. The course of the patient's response to treatment is shown in Figure 2 .
Additional Cases
In addition to the cases of the 2 patients highlighted above, 11 other patients have received ketamine infusion treatment at our center, 7 of whom showed some level of positive response at varying points, more so in the acute rather than in the maintenance phase. Patient 3, in her early 30s, was initially diagnosed with bipolar disorder, depressed phase with mood incongruent psychotic features, and multiple past suicide attempts. She received a single dose of ketamine infusion (50 mg/kg) in conjunction with lamotrigine (100 mg twice daily), olanzapine (25 mg/d), and buproprion (150 mg twice daily). Patient 3's active suicidal ideation with intent resolved 24 hours after the ketamine infusion, and she was discharged after a week's admission to the psychiatric ward, with remission of depression. Her diagnosis was revised to schizoaffective disorder 2 months later, in view of residual delusions of reference during her euthymic state.
Patient 4, a lawyer in his 50s with unipolar TRD, achieved functional remission after receiving 3 doses of ketamine infusion (2 weekly doses and another dose after 2 wk). Subsequent ketamine infusions were gradually stretched out to monthly doses. However, the patient started to develop tolerance to the effect of ketamine, in which he described a shorter duration of effect lasting only 5 days after ketamine infusion once the dosing was carried out monthly. He experienced a mild depressive relapse after 15 months and was not eager to continue serial ketamine infusions. Patient 4's depression subsequently improved on asenapine after some resolution of psychosocial stressors.
Two male patients in their 60s with TRD, one with bipolar depression (patient 5) and one with unipolar depression with comorbid social anxiety disorder (patient 6), experienced resolution of suicidal ideation after 7 doses of serial ketamine infusions administered at intervals of 1 to 3 weeks over 4 to 5 months. However, their level of depression remained somewhat static. Both of these patients received clonazepam in conjunction with multiple antidepressants and mood stabilizers during their treatment with ketamine infusions.
Patient 7, with bipolar TRD with lifetime rapidcycling specifier, experienced initial response to serial ketamine infusions. The patient described feeling very calm and reported that his "brain was empty of anxiety," albeit with some mild dissociative symptom of "things moving in slow motion," after the third dose of intravenous ketamine (50 mg/kg) administered 2 times a week in combination with a stable dose of quetiapine (600 mg/d), as part of treatment as usual that was initiated before recruitment into the RCT. (Note that, in this study, both treatment arms were permitted to continue stable doses of preexisting treatment as usual medications). The patient received the ketamine treatment arm in an RCT of serial ketamine versus ECT. This RCT was a singleblind study of ECT versus serial ketamine infusions, in which the efficacy and safety raters were blinded to treatment allocation; the patients, however, were not blinded to treatment allocation, in view of the difficulties of blinding a patient to ECT treatment. Ethical approval for this RCT (FF-2014-232) was granted by the Research Ethics Committee of the National University of Malaysia (there is no national trial registry in Malaysia). After the fifth dose of ketamine, patient 7's suicidal ideation resolved, and his depression was reduced by 60%. However, after the sixth ketamine dose, the patient was discontinued from the RCT because of a relapse of depression and reemergence of suicidal ideation. The patient was also observed to have a mild increase in goal-directed ideas, possibly signalling the development of a mixed episode. Inadequate optimization of mood stabilizers in the context of a history of rapid-cycling and current mixed mood state may have contributed to his overall poor response to serial ketamine infusions. After discontinuation from the RCT, the treatment arm (serial ketamine) was unblinded to the RCT study investigators, and urgent clinical care was initiated by the treating team. The patient subsequently received multiple courses of ECT and various combinations of mood stabilizers, but sustained remission has remained elusive for the past 19 months.
Patient 8, with unipolar TRD with an atypical specifier and severe suicidal ideation, experienced an initial response to serial ketamine infusions in combination with stable doses of escitalopram (20 mg) and aripiprazole (5 mg), as preexsiting treatment as usual while participating in the same RCT as patient 7, albeit with some signs of tolerance. Patient 8 received the serial ketamine treatment arm in this RCT. After the fifth ketamine dose, the patient said that his "brain felt lighter and physically lifted." After his sixth ketamine dose, he developed transient subthreshold hypomanic symptoms, raising the question of latent bipolarity unmasked by ketamine. After receiving 8 ketamine infusions administered twice a week as per the RCT protocol, his depressive symptoms were reduced by 50%, and his suicidal ideation had resolved. The patient was discontinued from the RCT 3 weeks after completion of serial ketamine infusions because of a relapse of depression and suicidal ideation. Subsequently, the patient responded to open-label (non-RCT) serial weekly intravenous ketamine in combination with lamotrigine in terms of resolution of suicidal ideation with minimal reduction of depressive symptoms. The patient described a transient but severe dissociative episode associated with intense negative emotions during his fifth open-label ketamine infusion.
Patient 9 received 3 courses of serial ketamine infusions with concomitant antidepressants and mood stabilizers for unipolar TRD. The patient received the first course of 8 doses in 2009, to which the patient started to respond (with some degree of mood elevation and resolution of passive death wishes) after the fourth dose (with doses administered twice a week), but she experienced some tolerance beginning with the fifth weekly dose (ie, a shorter duration of effect). In view of her inadequate response to ketamine (BDI = 35), this patient was given ECT in 2010. However, her response to ECT was also inadequate, and she received a second course of serial ketamine infusions (15 doses, administered either twice a week or weekly). The patient described experiencing some benefit from ketamine's antidepressant effect, although the effect was transient (lasting 2 to 3 d) . The patient preferred ketamine infusions over ECT (because of the more impairing cognitive side effects of ECT). She, therefore, requested a third course of ketamine during a severe depressive relapse (BDI = 50) in 2015. After 6 doses of weekly ketamine infusions, a trial of ketamine induction with ECT was attempted, but the benefit was minimal. Currently, this patient is in partial remission on maintenance unilateral ECT, after receiving a course of traumaspecific CBT, to address her comorbid chronic posttraumatic stress disorder (PTSD).
Four of the 11 patients who received ketamine infusion treatment did not show significant benefit overall. Patient 10 is a woman in her 50s with bipolar TRD (failed course of ECT) who received 28 doses of ketamine infusions (1 to 2 doses weekly) with adequate optimization of mood stabilizer medications. Even though minimal improvement in the patient's socio-occupational functioning was reported by her family members, she did not experience significant improvement in her depressive symptoms (static BDI scores). Psychosocial factors such as high expressed emotion in the family and challenges in receiving psychotherapy may have contributed as factors perpetuating her depression. The 3 other patients, patients 11, 12, and 13, were discontinued from serial ketamine infusions because of the risks of adverse events outweighing any potential benefit. Patient 11, a man in his 70s with unipolar TRD and comorbid hypertension, was discontinued from serial ketamine infusion after 5 doses given on a weekly to monthly basis because of inadequate response and also the risk of worsening his comorbid hypertension. This patient subsequently achieved partial remission from his depression with a course of ECT. Patient 12, a woman in her 60s with borderline hypertension, received 2 doses of weekly ketamine infusions for unipolar TRD. Ketamine treatment was stopped because of lack of response and worsening of the patient's hypertension. Subsequently, this patient's depression responded to a course of rTMS. Finally, patient 13, a man with bipolar TRD and comorbid obsessive compulsive disorder in his 30s, received 2 doses of weekly ketamine infusions. The patient did not experience significant benefit and was discontinued from ketamine treatment after the second dose because of intolerable side effects (ie, severe derealization during ketamine infusion and worsening of panic attacks after ketamine infusion).
DISCUSSION
The use of maintenance antidepressants in bipolar disorder remains controversial, especially in mixed episodes, in view of the risk of an antidepressantinduced switch to mania or dysphoria. 32 Apart from a case report describing the use of weekly ketamine infusions of 50 to 600 mg, administered over 5 months in combination with rTMS treatment, 33 in a patient with bipolar disorder with mixed features, evidence for the effectiveness of maintenance ketamine in mixed states of bipolar disorder is still lacking. In that 2015 case report, Hassamal et al 33 demonstrated the benefit of multiple courses of serial ketamine infusion during acute depressive episodes in achieving remission for 18 months in the context of treatment resistance to deep brain stimulation. The results for patient 1 described above suggest that ketamine infusion treatment may be effective in both the acute and maintenance phase (up to 7 mo) of treatment for a patient with bipolar disorder in a mixed state with high suicidality and alcohol dependence, in combination with adequate optimization of mood stabilizers and CBT for comorbid social anxiety disorder.
The course of treatment of patient 1 also illustrated that the patient's chronic benzodiazepine use, which was difficult to discontinue because of significant anxiety, was successfully tapered down with ketamine treatment in conjunction with CBT. Mood stability with ketamine treatment was markedly improved when concomitant benzodiazepine use was reduced. This observation is congruent with the finding that ketamine's antidepressant effects may be diminished by concurrent benzodiazepine use, [34] [35] [36] which may have contributed to the lack of antidepressant efficacy despite demonstrable antisuicidal effects in the cases of patients 5 and 6. Ketamine is a noncompetitive N-methyl-D-aspartate receptor antagonist. The pharmacodynamic interaction between ketamine and benzodiazepines likely involves modulation of GABA-(gamma-aminobutyric acid) ergic and glutamatergic pathways. 34 Enhancement of synaptogenesis and neural plasticity by glutamate modulation has been hypothesized as a mechanism of ketamine's antidepressant action. 17 Concomitant use of lamotrigine, an inhibitor of glutamate release, is thought to reduce the adverse effects of ketamine, such as perceptual disturbances, psychosis, and cognitive deficits, and may possibly even augment ketamine's mood-elevating effects in healthy volunteers, albeit transiently. 34 Patient 3 did not experience the above-mentioned adverse events before or after the addition of lamotrigine. An especially noteworthy treatment response effect was the marked improvement in terms of mood stability, when lamotrigine was optimized to a dose of 200 mg daily in combination with ketamine in patient 1, whereas previous combinations of lamotrigine and selective serotonin reuptake inhibitors were not effective. Whether the positive response to ketamine seen in the cases of patients 1 and 3 can be attributed to the synergistic effect of lamotrigine and ketamine in terms of antidepressant and antisuicidal effects remains to be clarified in future systematic and well-controlled studies.
The current evidence for ketamine's potential as an antisuicidal agent is very limited beyond its effect on reducing suicidal ideation. 9 Nevertheless, as illustrated in our first case report, a combination treatment strategy that includes serial ketamine, other pharmacological agents, and psychosocial interventions could potentially reduce recurrent suicide attempts in TRD. Longer term prospective studies are needed to determine the role of ketamine in preventing the progression of suicidal ideation to more serious suicidal acts such as suicide attempts and suicide.
The case reports of both patients 1 and 2 highlight the advantages of maintenance ketamine over ECT, especially in terms of fewer cognitive side effects and improved functioning. In the case of patient 1, ECT seemed to be more efficacious in reducing acute suicidality, but, given the cognitive side effects of ECT that the patient experienced, maintenance ketamine in combination with mood stabilizers and CBT was more effective in the longer term and eventually resulted in remission of mood symptoms and resolution of suicidality. In 2016, Lee et al 17 postulated that ketamine's procognitive effect might be a possible mechanism underlying ketamine's antisuicidal effect. The results of a single-blind RCT (N = 18) published by Ghasemi et al 37 in 2014 seemed to suggest a more rapid and efficacious antidepressant effect of ketamine compared with ECT at the initial stage of acute treatment. However, these authors did not find any significant differences in terms of efficacy between acute ECT and ketamine at 1 week posttreatment. Controlled studies comparing maintenance ketamine and ECT are needed not only to benchmark against ECT as the conventionally accepted "gold-standard" of TRD treatment, but also to determine the predictors of response to either treatment, which would better enable the practice of precision medicine rather than a trial and error approach according to current algorithms. Both patients 1 and 2 had a positive family history of alcohol dependence, which has been shown to be a predictor of good antidepressant response to ketamine, 14 and such a history also predicted a good antisuicidal effect in the case of patient 1. 19 Dissociative side effects may also predict a favorable antidepressant response. 16 Patients 1 and 2 reported mild dissociative symptoms, whereas patient 13 found such symptoms intolerable. These results underscore the variable responses to ketamine and the need to balance the risk and benefit of this treatment in each individual patient. Other predictors of a good antisuicidal effect of ketamine in patient 1 were a history of a suicide attempt 12 and previous psychiatric hospitalization. 19 What remains an unanswered challenge is determining how long maintenance ketamine should be continued. In particular, the balance is tenuous between the risk of relapse with discontinuation of an effective agent in the face of multiple failed trials of medications and ECT, and the uncertainties with regard to the best approach to monitor for potential side effects in the long-term, such as hepatotoxicity, cystitis, neurological adverse events, or potential dependence and abuse risks, 30 especially in the presence of coexisting alcohol dependence, as illustrated in our first case. One strategy is to adopt a gradually increasing interval duration between maintenance ketamine treatments while continuing other concomitant maintenance pharmacological treatments and reemphasizing psychosocial strategies for relapse prevention. This approach is consistent with the recommendation in the 2014 systematic review by Brown et al, 38 which is to use a combination of other antidepressants and flexible dosing of maintenance ECT according to indicators of potential relapse. Anecdotally, dosing schedules of ketamine infusions administered between once weekly and once every 3 weeks for up to 15 months have been reported to sustain remission. 39 In the case of patient 2, a dosing schedule of ketamine infusions every 4 to 5 weeks, administered over 90 minutes, seemed to be optimal over a period of 5 years. Other formulations, such as a dose of intranasal ketamine every 2 to 3 days, have been anecdotally reported to be useful for up to 26 months in a patient with TRD. 40 For practical purposes, a depot formulation of ketamine may be the way forward, as reported in a 2014 study by Gálvez et al, 41 which showed that a single subcutaneous administration of ketamine (0.2 mg/kg), in combination with nortryptiline for 5 months, in a patient with unipolar TRD resulted in sustained remission.
CONCLUSIONS
Both case reports 1 and 2 illustrate the potential benefits of longer term maintenance treatment with ketamine, beyond acute effectiveness, in combination with other conventional psychiatric medications and psychosocial interventions, in patients with bipolar and unipolar TRD with suicidal behavior. Ketamine treatment showed acute effectiveness in another 7 cases, especially in terms of reduction of suicidal ideation, albeit without significant long-term antidepressant effect. Inadequate mood stabilizer optimization is a likely factor for nonresponse to serial ketamine infusions in patients with bipolar spectrum disorders and TRD. Other factors that may contribute to nonresponse to longer term maintenance ketamine infusions include complex comorbidities and adverse events such as persistence of significant hypertension and severe dissociation. Current consensus guidelines 1 advocate an eventual tapering and discontinuation of maintenance ketamine treatment because of the lack of evidence for both long-term efficacy and safety beyond anecdotal reports. Nevertheless, there remains a minority subpopulation of ketamine responders among patients with ultra-TRD for whom indefinite maintenance ketamine under close vigilance may be warranted. Therefore, future well-designed controlled trials, with more feasible and practical formulations of ketamine treatment, are required to establish longer term (years) efficacy and safety of such therapy in TRD with suicidal behavior.
COMMENTARY BY DAVID A. KAHN, MD
When we first considered the article by Dr Chan and colleagues for publication, it consisted of 2 cases illustrating long-term success with ongoing intravenous ketamine. Maintenance-phase infusions, administered weekly, appeared to help sustain improvement for 7 months in 1 patient, and in another patient for 5 years (the longest course of treatment so far published), administered every 3 to 5 weeks. Both patients had failed to respond to electroconvulsive therapy but stabilized with ketamine along with careful, creative, sequential psychopharmacology and psychotherapy. Synergy between conventional treatment modalities and ketamine may have been instrumental. Although these were not pure trials by any means, the narratives were impressive. The editor asked the authors for more information about their ketamine experience, if possible the response rates across all of their cases, to place better in context the significance of these 2 successful outcomes. They generously responded with brief vignettes of 11 more patients. Of these, 7 had initial responses to ketamine, although most patients eventually relapsed and discontinued treatment. Four had no response. All 13 patients had significant comorbidities, including substance abuse, psychosis, trauma history, or personality disorder. Several, including the 2 lead cases, had failed to respond to electroconvulsive therapy. We feel that, despite the uncontrolled, anecdotal nature of these case reports, Chan and colleagues have given us the most extensive, transparent, real-world picture yet seen in the literature regarding what actually happens when ketamine is introduced into clinical practice, outside of a research protocol, to help complex patients with depressive symptoms. Although their sample cannot be analyzed statistically and is not comparable to carefully selected research populations of patients with major depressive disorder, the response and remission rates they observed for ketamine are not dissimilar to the third-stage medication steps in the STAR*D trial. 42 In that landmark study, patients who remained depressed after step 1 citalopram and step 2 augmentation with bupropion or buspirone went on to step 3 monotherapy with nortriptyline or mirtazapine. Remission rates in step 3 were under 20%-nearly identical to the long-term results in the current case report. Ketamine, in the off-label psychopharmacology universe, is at least step 3 and beyond. It is to be hoped that the striking short-term results seen in controlled research trials of ketamine for depression and suicidality will lead to mechanistically new antidepressant treatments that have real staying power. The long-term use of ketamine itself, with exploding, widespread off-label availability and no patent, will be almost impossible to study in a serious way. The best we can hope for is that a registry to aggregate data and standardize outcome measures will be developed among the growing number of practices and for-profit networks. In the meantime, it would be prudent both to lower our sights for the probability of long-term response, but also to keep our eyes open for the minority of patients for whom ketamine may prove transformative, just as we do with tricyclics, monoamine oxidase inhibitors, and other antidepressant medications and augmentations.
